New preclinical findings connect metabolic vulnerability and regulated cell death to overcome drug resistance and immune escape across cancer models. One report shows fingolimod (FTY720) reverses lenalidomide resistance in multiple myeloma by inducing ferroptosis through suppression of the NRF2/SLC7A11/GPX4 antioxidant axis. Another highlights a pathway in glioblastoma where an LDHA–lactate–HCAR1 axis supports an immunosuppressive macrophage state. Separately, a colorectal cancer study identified PRMT5-driven metabolic reprogramming that activates PD-L1 through lactate-mediated signaling, disabling antitumor immunity. Together, the studies keep metabolic control and ferroptosis/immune checkpoints tightly coupled in translational cancer biology.